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Background: Muscle carnosine is related to contractile function (Ca++ handling) and buﬀering of ex-
ercise–induced acidosis. As these muscular functions are altered in Multiple Sclerosis (MS) it is relevant to
understand muscle carnosine levels in MS.
Methods: Tibialis anterior muscle carnosine was measured in an animal MS model (EAE, experimental auto-
immune encephalomyelitis, n = 40) and controls (CON, n = 40) before and after exercise training (EAEEX,
CONEX, 10d, 1 h/d, 24m/min treadmill running) or sedentary conditions (EAESED, CONSED). Human m. vastus
lateralis carnosine of healthy controls (HC, n = 22) and MS patients (n = 24) was measured.
Results: EAE muscle carnosine levels were decreased (p< .0001) by ~ 40% to ~ 64% at 10d and 17d following
EAE induction (respectively) regardless of exercise (p = .823). Similarly, human MS muscle carnosine levels
were decreased (− 25%, p = .03).
Conclusion: Muscle carnosine concentrations in an animal MS model and MS patients are substantially reduced.
In EAE exercise therapy does not restore this.
1. Introduction
Multiple sclerosis (MS) is a neurodegenerative autoimmune disease
of the central nervous system (Pugliatti et al., 2006), in which in-
ﬂammatory and demyelination processes also result in physical in-
activity, decreased exercise capacity, excessive (post-exercise) fatigue
and reduced muscle contractile function (Dalgas et al., 2008; Savci
et al., 2005). These frequently occurring secondary symptoms sub-
stantially aﬀect various daily life activities, ultimately leading to an
impaired quality of life (Ellis and Motl, 2013). Central mechanisms (de
Haan et al., 2000; Kent-Braun et al., 1997; Rice et al., 1992; Sharma
et al., 1995; van der Kamp et al., 1991) such as reduced motor ﬁring
rates, impaired motor unit recruitment and increased central motor
conduction time clearly contribute to the above described disuse-re-
lated physiological proﬁle (Ng and Kent-Braun, 1997). A portion of the
neuromuscular dysfunction in MS however, probably also resides
within the skeletal muscle (de Haan et al., 2000; Garner and Widrick,
2003; Kent-Braun et al., 1997, 1994; Rice et al., 1992; Sharma et al.,
1995; Wens et al., 2014).
We, and others, already reported altered muscle ﬁber composition
(shift to glycolytic ﬁbers), disturbed muscle contractile characteristics
and cross-bridge (Ca2+ handling) abnormalities in muscles of MS pa-
tients (de Haan et al., 2000; Garner and Widrick, 2003; Wens et al.,
2014). Furthermore, reduced Krebs cycle and complex I and II activities
(Kent-Braun et al., 1997; Kumleh et al., 2006), overproduction of re-
active oxygen species (ROS) (Haider et al., 2011), increased basal AMP-
activated protein kinase phosphorylation (Hansen et al., 2015) and
delayed phosphocreatine resynthesis after exercise (Campbell et al.,
2013; Hansen et al., 2015; Kent-Braun et al., 1997, 1994; Kumleh et al.,
2006) suggest muscular mitochondrial dysfunction in MS and higher
basal and exercise-related energy expenditure. In keeping with this,
increased intramyocellular lactate accumulation, leading to increased
basal serum lactate concentrations (Amorini et al., 2014), have been
shown to cause greater (perceived) muscle fatigue in MS patients. It
thus seems that MS patients do not only exhibit central neurological
abnormalities but also impairments in both muscular contraction me-
chanisms and energy supply. In keeping with this, exercise rehabilita-
tion therapy, that amongst others induces muscular acidosis, has be-
come an important part of overall MS treatment (Motl and Gosney,
2008).
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So far, small but signiﬁcant improvements in exercise capacity and
muscle contractile characteristics following various types (modality,
frequency) of short to longer term regular exercise therapy have been
reported in both a frequently used animal MS model, notably
Experimental Autoimmune Encephalomyelitis (EAE) (Wens et al.,
2015b) and in MS (Kjolhede et al., 2012; Motl et al., 2008; Petajan
et al., 1996; Sallis et al., 1986; Schulz et al., 2004; Stuifbergen et al.,
2006). In an attempt to further improve muscle contractile and energy
metabolic responses to exercise, our laboratory recently performed high
(er) intensity training studies in MS showing substantially improved
(+25–50%) muscle strength and exercise capacity following 8–12w of
exercise (Wens et al., 2015a, 2015b). Although promising, most MS
subjects however reported higher post-exercise muscle fatigue and
overall perceived exertion rates (BORG: 14.7± 1.5 vs. 12.7±1.3)
compared to regular intensity training (Wens et al., 2014). Conse-
quently, any strategy that attenuates this may further improve therapy
outcome.
Carnosine, a dipeptide composed of β-alanine and L-histidine, is
found in high concentrations in mammalian skeletal muscle (Boldyrev
et al., 2013). Together with anserine or ophidine/balenine, the me-
thylated analogs that possess the same bioactivity and are exclusively
found in animals, carnosine forms the histidine-containing dipeptides
(HCD). The physiological role of carnosine is related to contractile
function in general and more speciﬁc to Ca++ handling (Derave et al.,
2010). Interestingly, carnosine has also been shown to buﬀer ex-
ercise–induced acidosis (Derave et al., 2010), to aﬀect mitochondrial
respiration (Boldyrev, 2007) and to protect against exercise-induced
oxidative stress (Dawson et al., 2002). The functional role of carnosine
in skeletal muscle is thus closely related to several of the above de-
scribed muscle alterations seen in MS. So far, altered tissue carnosine
concentrations were shown in other neurological diseases such as
Amyotrophic Lateral Sclerosis (ALS) (Stuerenburg and Kunze, 1999)
and Parkinson's Disease (Bellia et al., 2014; Boldyrev et al., 2013).
Moreover, reduced serum carnosinase activity was already found in
patients with MS (Wassif et al., 1994), indicating that several of the
above described muscle alterations like impaired exercise capacity,
excessive (post-exercise) fatigue and reduced muscle contractile func-
tion in MS (Dalgas et al., 2008; Savci et al., 2005; Wens et al., 2014)
may, in part, be related to reduced muscle carnosine levels. This,
however, has not been investigated in animal MS models and/or MS
yet. Finally, it is important to note that although the overall impact of
exercise on muscle carnosine content in healthy controls and disease is
contradictory (Baguet et al., 2011; Derave et al., 2007; Kendrick et al.,
2008, 2009; Mannion et al., 1994; Suzuki, 2004), increased muscle
carnosine has been shown to reduce exercise-induced fatigue and
hereby improve exercise performance during high-intensity inter-
mittent exercise (1–4min) (Blancquaert et al., 2015; Derave et al.,
2010, 2007). Therefore, the ﬁrst aim of this study is to investigate
muscle carnosine levels in both EAE animals and MS patients. We hy-
pothesize that muscle carnosine concentrations in EAE and MS are re-
duced compared to healthy controls. Secondly, the eﬀect of exercise on
muscle carnosine levels in EAE rats is explored.
2. Methods
Muscle carnosine content was measured in both an animal MS
model, notably Experimental Autoimmune Encephalomyelitis (EAE,
Part I), and MS patients (Part II). The analyzed muscle samples origi-
nate from studies that were previously performed and published by our
laboratories (Keytsman et al., 2017; Wens et al., 2015b).
2.1. Part I
In a ﬁrst phase, rodent muscle carnosine and anserine levels were
investigated using the EAE animal MS model (Constantinescu et al.,
2011). Brieﬂy, this model is characterized by the induction of EAE on
day 0, an inﬂammatory period with no clinical symptoms (day 0 to day
10) and gradual hindquarter paralysis (day 11 to day 14) followed by
almost full recovery (day 15 to day 17).
2.1.1. Animals
Eighty female Lewis rats (age 6–7 weeks, body weight 100–120 g,
Harlan CPB, Zeist, The Netherlands) were individually housed (12 h/
12 h light/dark cycle; temperature of 22 °C; relative humidity of
22–24%) in the animal facilities at Hasselt University. Rats were fed ad
libitum with water and normal rat pellets (Carﬁl RN-01-K12, Harlan).
The animal Ethics Committee of Hasselt University approved the study
protocol that complied with the national/European legislation and the
National Research Council's guide for the care and use of laboratory
animals.
2.1.2. Study design
Following acclimatization and adaptation (day − 21 to − 15),
animals were randomized into two subgroups: a sedentary group (SED,
n = 40) and an exercise group (EX, n = 40). In order to induce com-
parable levels of stress, SED animals were seated on the stationary
treadmill (1 h) on a daily basis (day −14 to 0). Daily food intake and
body weight were registered. At day 0, SED and EX groups were sub-
divided into a healthy control group (CONSED n = 20; CONEX n = 20)
and an EAE group (EAESED n = 20; EAEEX n = 20). Brieﬂy, EAE was
induced by a single percutaneous injection in both footpads (100 µl/
foot) under isoﬂurane anesthesia and consisted, per animal, of 24 µl
puriﬁed myelin basic protein (MBP, 25mg/ml) in combination with
25 µl 7RA heat-killed Mycobacterium Tuberculosis (20mg/ml, Difco),
120ùl complete Freunds adjuvant (CFA, Difco) and 31 µl phosphate-
buﬀered saline (PBS) (Polﬂiet et al., 2002). Hereafter, EX rats exercised
daily for 1 h/day, during 10 consecutive days, until progressive hind-
quarter paralysis prevented this. Treadmill performance/intensity was
visually monitored daily by the researchers and did not appear to be
diﬀerent between the control and EAE groups.
At day 10 (D10), just before onset of hindquarter paralysis, tread-
mill training was terminated and 10 animals of each group were eval-
uated. The remaining rats (n = 10 per group) endured hindquarter
paralyses (EAE group, day 11–14) and were evaluated after (almost
full) recovery on day 17 (D17). All animals were anaesthetized using an
intraperitoneal injection of pentobarbital sodium (5mg 100 g-1 BW)
and m. tibialis anterior (TA) of the right hind limb was dissected and
freed of connective tissue and visible blood. The mid-part of each
muscle was snap-frozen using liquid nitrogen, and stored at − 80 °C
until further analysis were performed. All animals were sacriﬁced after
muscle sampling.
Throughout the study course, animals were carefully monitored on
daily basis. Animals did not display severe discomfort immediately
following immunization. Paralysis and typical signs of EAE occurred 11
days post-immunization, which is the typical time frame for this animal
model. If animals exhibited signs of severe pain (high clinical score for
2 consecutive days), distress, were unable to reach food or when hu-
mane endpoints were reached, euthanasia to relief pain was performed.
However, none of the animals included in the study underwent eu-
thanasia for one of those reasons.
2.2. Part II
2.2.1. MS subjects
Twenty-two healthy controls (HC) and twenty-four patients with MS
(aged> 18 years; mean EDSS 3.1±1.5, range 0→6, median 2.5) were
included following written informed consent. Subjects were excluded if
they participated in other studies, had (in case of MS) an acute ex-
acerbation 6 months prior to the start of the study or had an EDSS
score> 6. Phenotypes of MS (RR, relapsing remitting; PP, primary
progressive; SP, secondary progressive) and the duration of the disease
were inventoried. The study was approved by the local Ethical
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Committee of the Jessa hospital and Hasselt University and complied
with the Declaration of Helsinki. This study was registered at
ClinicalTrials.gov (NCT02466165).
2.2.2. Muscle biopsies
Muscle biopsies were obtained from MS patients (n = 24) and HC (n
= 22) from the middle part of the m. vastus lateralis (Bergström needle
technique), by an experienced medical doctor. Biopsies were sampled
from the weakest leg, as assessed by a preceding isometric muscle
strength test performed on an isokinetic dynamometer (System 3,
Biodex, ENRAF-NONIUS, New York, USA). The biopsied leg of HC was
randomized, since muscle strength associated with each leg (left vs.
right or dominant vs. nondominant) is equal in healthy persons
(McCurdy and Langford, 2005; Siqueira et al., 2002). The sample was
freed from connective tissue and snap-frozen with liquid nitrogen and
stored at − 80 °C, until further analysis.
2.3. Muscle dipeptide and free amino acid content
Dipeptide and free amino acid concentrations were determined by
high-performance liquid chromatography (HPLC), as previously de-
scribed (Everaert et al., 2013). Muscle samples (15mg wet weight,
WW) were deproteinized using 35% sulfosalicylic acid and centrifuged
(5min, 16,000 g). Deproteinized supernatant (5 µl sample) was mixed
with AccQ Fluor Borate buﬀer (75 µl) and reconstituted Fluor Reagent
(20 µl) from the AccQTag chemistry kit (Waters). The derivatized
samples were applied to a Waters HPLC system comprised of an XBridge
BEH column (4.6 × 150mm, 2.5 µm) and ﬂuorescence detector (ex-
citation/emission wavelength: 250/395 nm). Carnosine and anserine
were assessed in Part I (animals) and carnosine, taurine, serine, gluta-
mine and histidine were measured in Part II (human subjects). To
compare muscle biopsy quality between healthy controls and MS, some
reference muscle amino acid (serine, histidine and glutamine, in Part II)
concentrations, expressed as total areas under the curve (tAUC), were
compared between groups. In case of normal serine, histidine and
glutamine concentrations, low carnosine concentrations could not be
due to poor biopsy quality.
2.4. Statistical analysis
All data were analyzed using SPPS v. 22.0 (IBM). Normality of data
distribution was evaluated using the Shapiro-Wilk test. In animals,
ANOVA was used to evaluate the (main and interaction) eﬀect of
‘group’ (CON vs. EAE), ‘activity’ (SED vs. EX) and ‘time’ (D10 vs. D17)
on carnosine and anserine concentrations and. For human analysis,
group comparison was performed using unpaired student's t-tests in
case of normality and non-parametric independent t-tests (Wilcoxon)
otherwise. All data are presented as means± SD and the threshold for
statistical signiﬁcance was set at p< .05.
3. Results
3.1. Part I
3.1.1. Rat muscle carnosine and anserine concentrations
Muscle carnosine concentrations were signiﬁcantly lower (main
group eﬀect, CON vs. EAE, p< .0001 range:− 40%→− 64%) in EAE
compared to CON and D10 to D17(main time eﬀect, D10 vs. D17, p =
.005, range: − 4% → − 46%)(Table 1). However, exercise had no
inﬂuence on carnosine concentrations (main activity eﬀect, SED vs. EX,
p = .823). No interaction eﬀects were found.
Muscle anserine was signiﬁcantly higher in EAE compared to CON
(main group eﬀect, CON vs. EAE, p = 0000, range: +36% → +40%).
No main activity and time eﬀects as well as interaction eﬀects were
detected.
3.2. Part II
3.2.1. Subject characteristics
Subject characteristics (Table 2) did not diﬀer between HC and MS.
Relapsing-remitting MS was diagnosed in 16 patients, whilst 6 patients
suﬀered from primary-progressive MS and 2 patients from the sec-
ondary- progressive form. Mean disease duration was 13± 8 years
(range 1→26 y).
3.2.2. Muscle carnosine and taurine content
In MS, muscle carnosine (3.8± 1.2 mmol/kg WW vs.
2.9± 1.3mmol/kg WW, p = .03) and muscle taurine
(8.4± 3.3mmol/kg WW vs. 6.5± 2.9mmol/kg WW, p = .04) levels
were lower compared to HC (Fig. 1). Total areas under the curve of
muscle serine (5.1± 2.7 vs. 4.3± 1.1, p = .12), histidine (6.2± 1.6
vs. 5.5± 1.5, p = .07) and glutamine (59.7± 30.3 vs. 61.1± 28.6, p
= .43) did not diﬀer between groups (data not shown).
4. Discussion
Compared to healthy controls the present study clearly shows re-
duced muscle carnosine levels in both human MS and a frequently used
Table 1
Rat muscle carnosine and anserine concentrations.
CONSED CONEX EAESED EAEEX
D10 D17 D10 D17 D10 D17 D10 D17
Carnosine 2.5± 0.6 2.2± 0.4 2.5±0.6 2.4± 1.1 1.5± 0.6 0.8±0.4 1.4± 0.3 0.9± 0.5
Anserine 2.2± 0.7 2.5± 0.4 2± 0.5 2.3± 1.0 3± 0.7 3.4±1.0 3.5± 0.7 2.9± 0.6
Data are expressed as means± SD and represent rat m. tibialis anterior carnosine and anserine concentrations (mmol/kg WW) 10 (D10, n = 10/group) and 17 (D17, n = 10/group) days
after acute experimental autoimmune encephalomyelitis induction (EAE) or healthy control (CON) under sedentary (CONSED, EAESED) or exercise (treadmill running, 1 h/d, 18m/min,
CONEX, EAEEX) conditions. Main eﬀects for group (CON vs. EAE, p = 0000) and time (D10 vs. D17, p = .005) were present for carnosine concentrations. For anserine concentrations, a
main group eﬀect (CON vs. EAE, p = 0000) was found.
Table 2
Baseline subject characteristics.
HC MS
Age (years) 48.7± 11.8 52.7± 8.9
Gender (f/m) 14/8 13/11
Weight (kg) 69.5± 13.8 71.6± 12.4
Height (m) 1.69± 0.1 1.71± 0.1
BMI 24.1± 2.4 24.5± 3.5
Disease duration (years) / 13± 8
EDSS / 3.1±1.5
Data are expressed as means± SD and represent subject characteristics (BMI: body mass
index) of healthy controls (HC, n = 22) and MS patients (n = 24). EDSS, Expanded
Disability Status Scale.
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animal MS model. Furthermore, in animals, exercise did not restore
carnosine concentrations. In MS, lower muscle carnosine was paralleled
by reduced taurine.
Literature indicates that carnosine metabolism could be altered in
neuromuscular diseases. Wassif et al. (1994) already demonstrated re-
duced serum carnosinase activity (− 49%) in fresh blood samples from
MS patients compared to healthy controls. Carnosinase causes hydro-
lysis of carnosine into β-alanine and L-histidine. This suggests altera-
tions in carnosine metabolism in patients with MS. Stuerenburg
(Stuerenburg and Kunze, 1999) investigated the carnosine content of
skeletal muscles from patients with suggestive neuromuscular diseases
and rats of various ages. Following stepwise regression modelling they
reported that another neurological disease such as ALS was negatively
correlated with muscle carnosine content and they suggested that this
was caused by progressive denervation processes, as also seen in MS.
Although altered tissue carnosine concentrations in other neuromus-
cular diseases such as ALS (Stuerenburg and Kunze, 1999) and Par-
kinson Disease (Bellia et al., 2014; Boldyrev et al., 2013) and reduced
serum carnosinase activity in MS (Wassif et al., 1994) were already
described, we are now the ﬁrst to report substantially reduced muscle
carnosine levels in an animal MS model and conﬁrm this in MS patients.
Apart from reduced muscle carnosine in EAE we also detected in-
creased muscle anserine concentrations. Interestingly anserine, the
methylated form of carnosine, is exclusively found in animals where it
possesses the same bioactivity as carnosine (Boldyrev et al., 2013).
Hence, when carnosine decreases and anserine tends to increase
(Table 1), the total amount of histidine-containing dipeptides (HCD)
remains unchanged. In order to keep the total HCD concentration
constant, it is possible that carnosine methyltransferase (CMT) is up-
regulated following EAE induction, leading to enhanced muscle an-
serine levels. Interestingly, Drozak et al. (2015) recently molecularly
identiﬁed UPF0586 protein C9orf41 as the mammalian carnosine-N-
methyltransferase, responsible for anserine formation in rat muscle
(Drozak et al., 2015). However, to date, no activity assay for CMT is
available. Quantitative PCR could be an alternative to measure the ef-
fect of EAE on CMT gene expression, but this is not always in agreement
with the amount of mRNA that is eﬀectively translated into protein. In
human subjects however, the methylated analog anserine is absent.
Therefore, in humans a decrease in muscle carnosine content implicates
an eﬀective reduction of the total histidine-containing dipeptide store.
Although the exact underlying mechanisms remain unclear, several
contributing factors may explain reduced carnosine stores in MS mus-
cles. In MS, central mechanisms (de Haan et al., 2000; Kent-Braun et al.,
1997; Rice et al., 1992; Sharma et al., 1995; van der Kamp et al., 1991),
such as impaired motor unit recruitment and delayed conduction/re-
action times induce a disuse-related physiological proﬁle (Ng and Kent-
Braun, 1997). In sedentary populations and in chronic disease (e.g. ALS,
osteoarthritis), lower muscle carnosine levels (Stuerenburg and Kunze,
1999; Tallon et al., 2007) have been reported that might result from an
inactivity related reduction in muscle protein content. However, in the
present study muscle histidine, glutamine and serine, that are also
prone to inactivity, were not aﬀected in MS muscle samples. As such,
we assume that the presented decrease in muscle carnosine content was
not due to poor biopsy or muscle quality. Possibly, several in-
tramyocellular dysfunctions that are associated with MS and relate to
the physiological role(s) of carnosine in muscle (Boldyrev et al., 2013),
could partly be related to the present ﬁndings. However, the exact ef-
fects of muscle carnosine on, amongst others, disturbed muscle con-
tractile characteristics and cross-bridge (Ca 2+ handling) abnormalities
(de Haan et al., 2000; Garner and Widrick, 2003; Wens et al., 2014),
excessive exercise-induced acidosis (de Haan et al., 2000; Kent-Braun
et al., 1997; Sharma et al., 1995) and mitochondrial dysfunction
(Campbell et al., 2013; Hansen et al., 2015; Kent-Braun et al., 1997,
1994; Kumleh et al., 2006; Sharma et al., 1995) in MS have not been
investigated yet.
The eﬀect of exercise therapy on muscle carnosine content is not
fully clear. With the exception of Suzuki (2004), who detected in-
creased carnosine concentrations after an 8 week sprint interval pro-
gram, most studies concerning this matter did not demonstrate positive
eﬀects after a 4–16 week isokinetic resistance training program
(Kendrick et al., 2008, 2009; Mannion et al., 1994) or a 5 week sprint-
training intervention (Baguet et al., 2011) on muscle carnosine con-
centrations in healthy subjects. The present study explored this in an
animal MS model and conﬁrmed that exercise therapy did not prevent
reduction of muscle carnosine. Possibly, nutritional interventions (e.g.
β-alanine supplementation) are required to exert such eﬀects.
Muscular carnosine concentrations are a good marker of the total
body carnosine stores, as> 99% of the compound is found in skeletal
muscle cells (Boldyrev et al., 2013). A reduction of total carnosine
stores is possibly also related to the increased oxidative stress and the
resulting accumulation of cytotoxic compounds, such as the reactive
carbonyls acrolein and hydroxynonenal (HNE). Carnosine serves as a
sacriﬁcial sequestering agent for acrolein and HNE by forming un-
reactive adducts (Song et al., 2014) and as such provides an en-
dogenous protective mechanism against protein and ultimately tissue
damage induced by these reactive carbonyls (Aldini et al., 2011; Baba
et al., 2013). The increased urinary elimination of carnosine-carbonyl
conjugates has been demonstrated for certain metabolic conditions
(metabolic syndrome, obesity, type-2 diabetes) that are characterized
by increased carbonyl stress (Regazzoni et al., 2016). Interestingly,
acrolein has also been implicated in the pathogenesis of MS, as it di-
rectly damages myelin, through reaction with protein and lipid com-
ponents of myelin, leading to demyelination. Furthermore, acrolein has
recently been identiﬁed as a promising and eﬀective therapeutic target
(Leung et al., 2011; Tully and Shi, 2013) in this population. In fact,
when Leung et al. (2011) treated EAE mice with the acrolein scavenger
hydralazine, myelin integrity appeared to be largely preserved in-
dicating that acrolein removal may oﬀer neuroprotection. Possibly,
Fig. 1. Muscle carnosine and taurine content of healthy controls and multiple sclerosis. Data represent m. vastus lateralis carnosine and taurine concentrations (mmol/kg WW) of healthy
controls (HC, n = 22) and MS patients (n = 24). *p< .05 between HC and MS.
C. Keytsman et al. Multiple Sclerosis and Related Disorders 21 (2018) 24–29
27
reduced muscle carnosine content in MS results from the incapacity of
endogenous carnosine synthesis to compensate for the increased ‘con-
sumption’ of carnosine to detoxify and eliminate acrolein. According to
this line of reasoning, nutritional strategies to improve muscle carno-
sine content in persons with MS are worthwhile to explore. Carnosine
supplementation (~ 1.5 g/d β-alanine) has already been shown to im-
prove a number of neurological symptoms (Boldyrev et al., 1987) in
Alzheimer's (Preston et al., 1998) and Parkinson's (Boldyrev et al.,
2013) disease. Clinically, nutritional interventions that normalize or
even elevate the reduced muscle carnosine content could therefore be a
valid new approach to improve muscle contractile properties, myocel-
lular energy supply and/or possibly neurological symptoms in MS.
Moreover, MS patients would be able to exercise more eﬃciently at
higher intensities leading to a better clinical rehabilitation therapy
outcome in these patients.
4.1. Limitations
The present study holds certain limitations that should be taken into
account regarding future research. We show that EAE and MS reduce
muscle carnosine, though because no nerve tissue was collected it was
not possible to investigate whether this was due to neuroaxonal injury
and/or muscle denervation. It is therefore warranted that in future EAE
research nerve tissue is sampled to investigate peripheral nerves, motor
end-plates and the extent of both neuronal and axonal damage in the
spinal cord. In MS, future studies should also investigate spinal cord
lesion load.
The current paper describes a reduction in muscle carnosine con-
centrations in an EAE group, compared to control animals. However, in
order to determine whether reduced muscle carnosine levels were ac-
tually related to EAE itself, a control group with injection of Complete
Freund's Adjuvant alone, causing inﬂammatory processes, would be
appropriate. Indeed, the injection of CFA may have caused local in-
ﬂammation and thus inﬂuenced m. tibialis anterior carnosine con-
centrations. This issue may also be addressed by unilateral immuniza-
tion and comparison of muscle carnosine of the two hind limbs.
Furthermore, for future carnosine related research in MS, assessment of
fatigue levels and dietary habits is worthwhile.
In summary, under the conditions of the present study EAE and MS
reduce skeletal muscle carnosine levels. Exercise therapy alone could
not prevent this in the animal MS model. This warrants further research
investigating the eﬀect of nutritional interventions that restore muscle
carnosine levels either or not in combination with exercise therapy.
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